Lumiflam BR Tablet is a combination pharmaceutical formulation containing Bromelain 180 mg, Trypsin 96 mg, and Rutoside 200 mg, designed to provide anti-inflammatory, analgesic, and vascular protective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, exhibits potent anti-inflammatory and fibrinolytic properties, facilitating the reduction of edema and promoting tissue repair. Trypsin, another proteolytic enzyme, aids in the degradation of inflammatory mediators and necrotic tissue, enhancing the resolution of inflammation and accelerating healing processes. Rutoside, a bioflavonoid, contributes to vascular health by strengthening capillary walls, reducing capillary permeability, and exerting antioxidant effects, thereby minimizing microvascular bleeding and edema. The synergistic action of these agents makes Lumiflam BR Tablet effective in managing conditions characterized by inflammation, pain, and vascular fragility, such as post-traumatic edema, phlebitis, and postoperative swelling. It is commonly prescribed as an adjunct therapy to reduce inflammation and promote recovery in musculoskeletal injuries and inflammatory disorders. The tablet should be used under medical supervision, considering contraindications such as hypersensitivity to any component, bleeding disorders, or concurrent anticoagulant therapy. Adherence to prescribed dosage and duration is essential to optimize therapeutic outcomes and minimize adverse effects.